In a smoker with hemoglobin 170 g/L and hematocrit 0.51, what is the likely diagnosis and appropriate management?

Smoker's Polycythemia: Diagnosis and Management

This patient most likely has smoker's polycythemia (secondary erythrocytosis from carbon monoxide exposure), and the primary treatment is smoking cessation, which will normalize hematocrit levels within weeks to months.

Diagnostic Considerations

The hemoglobin of 170 g/L (17 g/dL) and hematocrit of 0.51 (51%) in a smoker strongly suggests smoker's polycythemia rather than polycythemia vera (PV). Key distinguishing features include:

• Elevated carboxyhemoglobin levels (mean 11.6% in smokers vs. <1% normal) cause a left-shifted oxygen-hemoglobin dissociation curve, triggering compensatory erythrocytosis 1
• Both absolute and relative erythrocytosis occur, with increased red cell volume in 78% and reduced plasma volume in 78% of affected smokers 1
• JAK2 mutation testing is essential to exclude PV, as this would be negative in smoker's polycythemia 2

Critical Pitfall to Avoid

Measure carboxyhemoglobin levels in all polycythemic smokers—this should be routine in the evaluation 1. Missing this diagnosis leads to unnecessary workup for PV and delays appropriate intervention.

Immediate Management Steps

1. Confirm the Diagnosis

• Measure carboxyhemoglobin level to document carbon monoxide exposure 1
• Check JAK2 V617F mutation to exclude polycythemia vera 2
• Assess serum erythropoietin level—typically normal or elevated in secondary polycythemia, low in PV 3

2. Primary Treatment: Smoking Cessation

Smoking cessation is the definitive treatment and produces rapid, dramatic improvements:

• Hematocrit normalizes within 2 weeks after cessation in most patients 4
• All hematological parameters (hemoglobin, hematocrit, red cell count) show rapid return toward normal 4
• Complete normalization of all hematological parameters may take up to 5 years, though most changes occur within 2 years 5
• Symptoms resolve completely (fatigue, headache, syncope) in patients who successfully reduce or quit smoking 1

3. Alternative Harm Reduction Strategy

For patients unable to quit completely:

• Heat-not-burn tobacco as a transitional strategy can reduce hematocrit equivalently to complete cessation (47.51% vs. 45.63%, p=0.605) 6
• This approach improved hematocrit and smoking-related symptoms in patients with smoker's polycythemia who found complete cessation difficult 6
• Note: Even e-cigarettes can cause polycythemia, as documented in case reports 7, so complete cessation remains the gold standard

4. Phlebotomy Considerations

Judicious phlebotomy to hematocrit 55-60% may be reasonable if:

• Symptoms of hyperviscosity are present (headache, vertigo, visual disturbances) 3
• Smoking cessation efforts are ongoing but hematocrit remains elevated 3
• Avoid aggressive phlebotomy below this range, as the physiological benefit of increased oxygen-carrying capacity may outweigh risks in the 40-55% range 2

Expected Clinical Course

Patients typically experience:

• Symptomatic improvement including resolution of fatigue, headache, and numbness within weeks 1, 6
• Hematocrit reduction beginning within 2 weeks and continuing over months 4
• Reduced thrombotic risk as hematocrit normalizes, though specific data on thrombosis rates in smoker's polycythemia are limited compared to PV 3

When to Suspect Polycythemia Vera Instead

Proceed with full PV workup if:

• JAK2 V617F mutation is positive (present in >97% of PV cases) 2
• Low serum erythropoietin level (<reference range) 2
• Persistent elevation after smoking cessation for 2-5 years 5
• Bone marrow histology showing hypercellularity with trilineage growth 2